Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Karl-Heinz Schlemmer is active.

Publication


Featured researches published by Karl-Heinz Schlemmer.


BMC Pharmacology | 2007

Design and synthesis of the first NO- and haem-independent sGC activator BAY 58–2667 for the treatment of acute decompensated heart failure

Michael G Hahn; Cristina Alonso-Alija; Friederike Stoll; Markus Heil; Joachim Mittendorf; Karl-Heinz Schlemmer; Frank Wunder; Johannes-Peter Stasch

Soluble guanylate cyclase (sGC) is a signal-transduction enzyme activated by nitric oxide (NO) and plays a key role in a variety of physiological processes such as vasodilatation, antiaggregation, antiproliferation and neuronal signaling as well as in a variety of disorders of these functions. Current therapies that involve the use of organic nitrates and other NO donors have limitations, including non-specific interactions of NO with various biomolecules and lack of response and the development of tolerance [1,2]. Compounds that activate sGC in an NO-independent manner might therefore provide considerable therapeutic advantages.


Archive | 2007

Heterocyclic substituted, anellated pyrazole derivative and its uses

Hartmut Schirok; Nils Griebenow; Chantal Fürstner; Joachim Mittendorf; Johannes-Peter Stasch; Frank Wunder; Karl-Heinz Schlemmer; Stefan Heitmeier; Friederike Stoll


Archive | 2002

1 4-dihydro-1 4-diphenylpyridine derivatives

Haertwig Heike Gielen; Volkhart Min-Jian Li; Ulrich Rosentreter; Karl-Heinz Schlemmer; Swen Allerheiligen; Kevin Nash; Mary F. Fitzgerald


Archive | 2001

Selective pde 2 inhibitors, used as medicaments for improving cognition

Frank-Gerhard Böss; Martin Hendrix; Gerhard Konig; Karl-Heinz Schlemmer; R. Schreiber; Der Staay Franz-Josef Van; Dagmar Schauss; Ulrich Niewöhner


Archive | 2003

Heterocyclically substituted imidazotriazines

Martin Hendrix; David Brückner; Arno Friedl; Irene Gerlach; Volker Hinz; Jörg Keldenich; Frank Mauler; Ulrich Niewöhner; Maria Theresia Niewohner; Dagmar Karthaus; Karl-Heinz Schlemmer; Adrian Tersteeger; Ozkan Yalkinoglu


Archive | 2008

Substituierte Oxazolidinone und ihre Verwendung

Alexander Straub; Thomas Lampe; Jens Pohlmann; Susanne Roehrig; Elisabeth Perzborn; Karl-Heinz Schlemmer


Archive | 2003

Substituted alkyl uracils and thereof

Barbara Albrecht; Michael Gerisch; Michael Härter; Thomas Krahn; Felix Oehme; Karl-Heinz Schlemmer; Henning Steinhagen


Archive | 2004

Imidazo[1,3,5]triazinones and their use

Ulrich Niewöhner; Helmut Haning; Thomas Lampe; Mazen Es-Sayed; Gunter Schmidt; Erwin Bischoff; Klaus Dembowsky; Elisabeth Perzborn; Karl-Heinz Schlemmer


Archive | 2003

Isophtalic acid derivatives

Michael Härter; Jens Ergüden; Frank Wunder; Hanna Tinel; Johannes Köbberling; Eva-Maria Becker; Klaus Münter; Karl-Heinz Schlemmer; Raimund Kast; Peter Kolkhof; Gunter Karig; Lars Bärfacker; Walter Hübsch; Joachim Schuhmacher; Susanne Zuleger; Arnel Concepcion; Haruka Shimizu


Archive | 2002

Imidazotriazinones derivatives and their use against inflammatory processes and/or immune diseases

Cristina Alonso-Alija; Heike Gielen; Martin Hendrix; Dagmar Schauss; Hilmar Bischoff; Nils Burkhardt; Volker Geiss; Karl-Heinz Schlemmer; Nigel Cuthbert; Mary F. Fitzgerald; Graham Sturton; Ulrich Niewöhner

Collaboration


Dive into the Karl-Heinz Schlemmer's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge